Coherus BioSciences Inc logo

Coherus BioSciences Inc

1
NAS:CHRS (USA)  
$ 2.38 -0.03 (-1.24%) 11:08 PM EST
At Loss
Market Cap:
$ 268.26M
Enterprise V:
$ 636.43M
Volume:
1.85M
Avg Vol (2M):
3.18M
Also Trade In:
Volume:
1.85M
At Loss
Avg Vol (2M):
3.18M

Business Description

Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 0.25
Equity-to-Asset -0.31
Debt-to-Equity -2.49
Debt-to-EBITDA -2.48
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.67
Distress
Grey
Safe
Beneish M-Score -1.43
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Revenue Growth Rate -21.7
Name Current Vs Industry Vs History
5-Day RSI 53.76
9-Day RSI 51.92
14-Day RSI 50.49
6-1 Month Momentum % -39.02
12-1 Month Momentum % -63.24

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.43
Quick Ratio 1.24
Cash Ratio 0.35
Days Inventory 129.28
Days Sales Outstanding 235.47
Days Payable 62.6

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -15.7
Shareholder Yield % -34.97

Financials (Next Earnings Date:2024-05-08 Est.)

CHRS's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:CHRS

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Coherus BioSciences Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 257.244
EPS (TTM) ($) -2.6
Beta 0.67
Volatility % 97.83
14-Day RSI 50.49
14-Day ATR ($) 0.189107
20-Day SMA ($) 2.312
12-1 Month Momentum % -63.24
52-Week Range ($) 1.4301 - 8.65
Shares Outstanding (Mil) 112.71

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Coherus BioSciences Inc Filings

Filing Date Document Date Form
No Filing Data

Coherus BioSciences Inc Stock Events

Financials Calendars
Event Date Price($)
No Event Data

Coherus BioSciences Inc Frequently Asked Questions

What is Coherus BioSciences Inc(CHRS)'s stock price today?
The current price of CHRS is $2.38. The 52 week high of CHRS is $8.65 and 52 week low is $1.43.
When is next earnings date of Coherus BioSciences Inc(CHRS)?
The next earnings date of Coherus BioSciences Inc(CHRS) is 2024-05-08 Est..
Does Coherus BioSciences Inc(CHRS) pay dividends? If so, how much?
Coherus BioSciences Inc(CHRS) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1